756524-92-2

Upstream product

• 58931-16-1 1-(benzyloxy)-4-penten-2-ol 
• 106-95-6 allyl bromide 
• 60656-87-3 benzyloxyacetoaldehyde 
• 100-39-0 benzyl bromide 
• 796077-38-8 benzyloxy-acetic acid butyl ester 

Downstream Products

• 1426136-48-2 2-(benzyloxymethyl)-5,5-difluorotetrahydro-2H-pyran 
• 1239018-95-1 6-((benzyloxy)methyl)dihydro-2H-pyran-3(4H)-one 
• 1239018-94-0 6-((benzyloxy)methyl)tetrahydro-2H-pyran-3-ol 
• 194861-23-9 2-((benzyloxy)methyl)-3,4-dihydro-2H-pyran 
• 1426132-74-2 N-(5-(5-(5,5-difluorotetrahydro-2H-pyran-2-yl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 89429-82-3 6-benzyloxymethyl-3,4-dihydro-2H-pyran 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

Ruthenium-catalyzed olefin metathesis double-bond isomerization sequence

A novel ruthenium-catalyzed tandem ring-closing metathesis (RCM) double-bond isomerization reaction is described in this paper. The utility of this method for the efficient syntheses of five-, six-, and seven-membered cyclic enol ethers is demonstrated. It relies on the conversion of a metathesis-active ruthenium carbene species to an isomerization-active ruthenium-hydride species in situ. This conversion is achieved by using various additives. Scope and limitations of the different protocols are discussed, and some mechanistic considerations based on 31P and 1H NMR spectroscopic studies are presented.